Traded Nov 12 – Nov 13, 2026 · largest single transaction ~$7.3K
Show all 2 transactions
Nov 12, 2026~$7.3K · 9,000 sh @ $0.8136
DetailsOfficial recordNov 13, 2026~$2.5K · 3,000 sh @ $0.8334
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PHIO · NASDAQ · Pharmaceutical Preparations
Phio Pharmaceuticals (PHIO) · oqro.io/stocks/PHIO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.656−0.059 (−8.25%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
11 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Nov 12 – Nov 13, 2026 · largest single transaction ~$7.3K
Nov 12, 2026~$7.3K · 9,000 sh @ $0.8136
DetailsOfficial recordNov 13, 2026~$2.5K · 3,000 sh @ $0.8334
DetailsOfficial recordTraded Nov 10 – Nov 11, 2026 · largest single transaction ~$5.7K
Nov 10, 2026~$5.7K · 6,800 sh @ $0.8395
DetailsOfficial recordInsider buying
11 days before an 8-KTraded Nov 9 · filed 1 day later
Since the trade −21.9% · S&P 500 −8.3% · to Nov 20
Bought within 5% of the 52-week low, RSI 41, 22% under its 200-day average, 21 points behind the S&P 500 over 3 months
Insider buying
11 days before an 8-KTraded Nov 9 · filed 1 day later
Since the trade −21.9% · S&P 500 −8.3% · to Nov 20
Bought within 5% of the 52-week low, RSI 41, 22% under its 200-day average, 21 points behind the S&P 500 over 3 months
Traded Sep 28 – Sep 29, 2026 · largest single transaction ~$5.2K
Sep 28, 2026~$5.2K · 5,000 sh @ $1.03
DetailsOfficial recordInsider buying
4 days before an 8-KTraded Sep 24 · filed 1 day later
Since the trade −35.7% · S&P 500 −10.1% · to Nov 20
Bought 59% below the 52-week high, RSI 44, 8% under its 200-day average
Insider buying
6 days before an 8-KTraded Sep 22 · filed 1 day later
Since the trade −34.4% · S&P 500 −10.8% · to Nov 20
Bought 60% below the 52-week high, RSI 40, 10% under its 200-day average
Insider buying
13 days before an 8-KTraded Sep 15 · filed 1 day later
Since the trade −35.7% · S&P 500 −8.9% · to Nov 20
Bought 59% below the 52-week high, RSI 41, 9% under its 200-day average
Insider buying
Largest insider buy since 2013Traded Aug 19 · filed 1 day later
Since the trade −43.0% · S&P 500 −10.3% · to Nov 20
Bought 54% below the 52-week high, RSI 62
A Phio Pharmaceuticals director paid $17K out of pocket for Phio Pharmaceuticals shares. 2 other people at Phio Pharmaceuticals bought some too, in the same month.
Insider buying
Traded Aug 18 · filed 1 day later
Since the trade −37.5% · S&P 500 −10.1% · to Nov 20
Bought 58% below the 52-week high, RSI 49, 9% under its 200-day average
The CEO of Phio Pharmaceuticals paid $11K out of pocket for Phio Pharmaceuticals shares. 2 other people at Phio Pharmaceuticals bought some too, in the same month.
Insider buying
Their largest buy since 2013Traded Jun 26 · filed 3 days later
Since the trade −32.4% · S&P 500 −5.4% · to Nov 20
Bought 65% below the 52-week high, RSI 36, 29% under its 200-day average, 36 points behind the S&P 500 over 3 months
Traded Dec 23 – Dec 31, 2025 · largest single transaction ~$5.2K
Dec 31, 2025~$5.2K · 5,000 sh @ $1.03
DetailsOfficial recordInsider buying
Traded Nov 21, 2025 · filed 3 days later
Since the trade −41.4% · S&P 500 +4.7% · to Nov 20
Bought 83% below the 52-week high, RSI 18, 44% under its 200-day average, 46 points behind the S&P 500 over 3 months
The CEO of Phio Pharmaceuticals paid $5.7K out of pocket for Phio Pharmaceuticals shares.
Insider buying
Traded Nov 18, 2025 · filed 1 day later
Since the trade −48.4% · S&P 500 +4.5% · to Nov 20
Bought 81% below the 52-week high, RSI 22, 36% under its 200-day average, 41 points behind the S&P 500 over 3 months
The CEO of Phio Pharmaceuticals paid $6.3K out of pocket for Phio Pharmaceuticals shares.
Insider buying
Traded Jun 10, 2025 · filed 1 day later
Since the trade −73.4% · S&P 500 +14.4% · to Nov 20
A Phio Pharmaceuticals director paid $6K out of pocket for Phio Pharmaceuticals shares. 1 other person at Phio Pharmaceuticals bought some too, in the same month. Shares held went up 19% with this purchase.
Traded Jun 9 – Jun 10, 2025 · largest single transaction ~$4.8K
Jun 10, 2025~$4.8K · 2,000 sh @ $2.42
DetailsOfficial recordTraded May 21 – May 22, 2025 · largest single transaction ~$5.3K
May 21, 2025~$5.3K · 3,000 sh @ $1.77
DetailsOfficial recordInsider buying
Traded May 20, 2025 · filed 1 day later
Since the trade −64.2% · S&P 500 +16.4% · to Nov 20
A Phio Pharmaceuticals director paid $4.5K out of pocket for Phio Pharmaceuticals shares. 1 other person at Phio Pharmaceuticals bought some too, in the same month. Shares held went up 23% with this purchase.
Nov 11, 2026~$4.4K · 5,200 sh @ $0.838
DetailsOfficial recordSep 29, 2026~$5.2K · 5,000 sh @ $1.04
DetailsOfficial recordDec 23, 2025~$5.1K · 5,000 sh @ $1.02
DetailsOfficial recordJun 9, 2025~$4.1K · 1,500 sh @ $2.75
DetailsOfficial recordMay 22, 2025~$2.1K · 1,200 sh @ $1.78
DetailsOfficial record14 open-market purchases and 0 open-market sales by insiders of PHIO between Feb 3, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 5, 2026. The data provider lists the next release for Mar 3, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 5, 2026 | None | None | 6 purchases |
| Aug 6, 2026 | None | None | 2 purchases |
| May 7, 2026 | None | None | None |
| Mar 5, 2026 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies